COMP <GO>
ICCC vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
ImmuCell Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ICCC 1
— ABBV 11
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $10.32 (-2.82%) • MKT CAP: $93.7M
roic
4.20%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICCC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICCC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.40% | 70.20% | -28.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 4.20% | 29.00% | -24.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.9x | 33.3x | +2.60 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.31% | 3.47% | -2.16 | ABBV | /fcf-yield <GO> |
| Operating Margin | 6.00% | 24.60% | -18.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -3.80% | 6.90% | -10.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 8.60% | -4.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.28 | 5.33 | -1.05 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ICCC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 65.1 | -14.62 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $93.7M | $513.86B | -$513.77B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICCC REV | ABBV REV | ICCC GROSS % | ABBV GROSS % | ICCC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $27.6M | $61.16B | 41.4% | 70.2% | $1.2M | $17.82B |
| FY 2024 | $26.5M | $56.33B | 30.0% | 70.0% | -$107.8K | $17.83B |
| FY 2023 | $17.5M | $54.32B | — | — | -$4.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICCC // BETA —
ABBV // BETA 1.15